SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-011605
Filing Date
2023-04-03
Accepted
2023-04-03 16:28:35
Documents
17
Period of Report
2023-03-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cyt-20230329.htm   iXBRL 8-K 65442
2 EX-10.1 cyt-ex10_1.htm EX-10 54071
3 GRAPHIC img10298278_0.jpg GRAPHIC 60418
4 GRAPHIC img10298278_1.jpg GRAPHIC 84748
5 GRAPHIC img10298278_2.jpg GRAPHIC 79686
6 GRAPHIC img10298278_3.jpg GRAPHIC 127144
  Complete submission text file 0000950170-23-011605.txt   736218

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cyt-20230329.xsd EX-101.SCH 2443
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cyt-20230329_pre.xml EX-101.PRE 11412
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cyt-20230329_lab.xml EX-101.LAB 13887
11 EXTRACTED XBRL INSTANCE DOCUMENT cyt-20230329_htm.xml XML 4896
Mailing Address 99 HAYDEN STREET BUILDING B, SUITE 450 LEXINGTON MA 02421
Business Address 99 HAYDEN STREET BUILDING B, SUITE 450 LEXINGTON MA 02421 857-285-4140
Cyteir Therapeutics, Inc. (Filer) CIK: 0001662244 (see all company filings)

IRS No.: 455429901 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40499 | Film No.: 23793084
SIC: 2834 Pharmaceutical Preparations